Healthy Living Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.

Press releases published on September 15, 2026

Sep. 15, 2026

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Indeterminate GlobeNewswire

Sep. 15, 2026

Satellos to Present at the 31st Annual Congress of the World Muscle Society

Indeterminate GlobeNewswire

Sep. 15, 2026

Juniper Biosciences Unveils JBS-002 and JBS-004, Advancing Two Late-Stage Diagnostic Programs to Registration Batch Manufacturing in the Fourth Quarter of 2026

Indeterminate GlobeNewswire

Sep. 15, 2026

Art Meets Whiskey: Breckenridge Distillery Debuts Limited-Edition Collectors Series Release with Pat Milbery

Indeterminate GlobeNewswire

Sep. 15, 2026

VitalHub Announces Expansion of AI Capabilities with Launch of AI Scribe

Indeterminate GlobeNewswire

Sep. 15, 2026

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Indeterminate GlobeNewswire

Sep. 15, 2026

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Indeterminate GlobeNewswire

Sep. 15, 2026

Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency

Indeterminate GlobeNewswire

Sep. 15, 2026

Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease

Indeterminate GlobeNewswire

Sep. 15, 2026

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Indeterminate GlobeNewswire

Sep. 15, 2026

Profusa, Inc. Receives Nasdaq Compliance Determination

Indeterminate GlobeNewswire

Sep. 15, 2026

TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026

Indeterminate GlobeNewswire

Sep. 15, 2026

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program

Indeterminate GlobeNewswire

Sep. 15, 2026

Hummingbird Bioscience Appoints Dr. James Garner as President

Indeterminate GlobeNewswire

Sep. 15, 2026

ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections

Indeterminate GlobeNewswire

Sep. 15, 2026

One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD

Indeterminate GlobeNewswire

Sep. 15, 2026

Eleva separates Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies

Indeterminate GlobeNewswire

Sep. 15, 2026

Children’s National ranked among top children’s hospitals nationwide and highest in the DMV by U.S. News & World Report

Indeterminate GlobeNewswire

Sep. 15, 2026

UPDATE – CAPHRA announces the Asia-Pacific Declaration call for Safer Nicotine Access

Indeterminate GlobeNewswire

Sep. 15, 2026

CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)

Indeterminate GlobeNewswire